SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Mucosal Lentiginous MelanomaAcral Lentiginous Malignant Melanoma
Interventions
DRUG

Sunitinib

Trial Locations (5)

37212

Vanderbilt University, Nashville

63110

Washington University in St. Louis, St Louis

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Pfizer

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00577382 - SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | Biotech Hunter | Biotech Hunter